SRT-100™: The Best Mohs Surgery Alternative
Since the 1930s, doctors have successfully treated various forms of skin cancer, including basal cell carcinoma and squamous cell carcinoma, the most common forms of skin cancer, using Mohs micrographic surgery. Today, Mohs surgery is the most widely accepted and utilized treatment for skin cancer with cure rates of over 98%.
However, there are many downsides to Mohs surgery. Because the estimation of how much tissue that needs to be removed to excise the skin cancer cells occurs during the operation, there is no for sure answer of how deep into the skin surgeons must cut and how long the procedure will last. In cases of deeply rooted cancers, patients can be stuck with disfiguring scars requiring reconstructive plastic surgery and lengthy recovery periods. Additionally, many patients diagnosed with basal cell or squamous cell carcinoma are of an age where diabetes, heart disease, and other medical conditions can lead to serious complications during surgery.
Luckily, there is another solution for the treatment of non-melanoma skin cancers like basal celland squamous cell carcinoma.
The SRT-100™: The Best Mohs Surgery Alternative
The SRT-100™ brings about a revolution in the field of non-melanoma skin cancer treatment.
1. Excellent Cure Rates
Superficial Radiation Therapy has proven to cure basal cell and squamous cell skin cancers over
95% of the time.
2. Short Treatment Time
Because there is no surgery involved, patients can be in and out of treatment sessions very
quickly. There is also no downtime, so patients can continue living their lives as normal.
3. No Surgery
No surgery means no anesthesia, no cutting, no bleeding, no stitching, and no pain.
4. No Post-Treatment
Mohs surgery patients often require reconstructive surgery to make up for the unsightly
scarring left from the procedure. With the SRT-100™, this is no longer necessary.
Are you interested in learning more about the SRT-100™ as a Mohs surgery alternative for your
practice? Contact Sensus Healthcare today.